SYBD NEWS
Synthetic Blood Reaches First Half of Traumatic Brain Injury Trial
COSTA MESA, Calif.--(BUSINESS WIRE)--May 19, 2006--Synthetic Blood International, Inc. (OTCBB:SYBD) today announced treatment of the fourth patient in its eight-patient Phase II proof-of-concept Oxycyte(TM) study in traumatic brain injury. Cerebral oxygen tension following Oxycyte administration was significantly increased in this patient, consistent with the results in the first three patients.
"We are pleased with the initial results at the halfway point in this trial," said Robert N. Nicora, Synthetic Blood President and CEO. "Decreased brain oxygen in severe brain injuries is implicated in poor functional outcome and even death. Brain damage as a result of decreased oxygen to the brain is found in about 80% of patients that die with severe head injuries. Animal and clinical studies have shown that increasing brain oxygen in such patients improves functional outcome, and Oxycyte has been shown to be an effective means of delivering oxygen to tissues, including the brain. The fact that we have seen increased oxygen levels in all four study patients strengthens our belief that administering Oxycyte to patients with traumatic brain injury and other ischemic states could improve clinical outcomes
Stock was up 23.43% on friday with abnormal volume
Signal and sentiment is rising
"Luck is what happens when preparation meets opportunity."
